BlackRock Discloses 5.1% Stake in Actinium Pharma
Ticker: ATNM · Form: SC 13G · Filed: Jan 29, 2024 · CIK: 1388320
| Field | Detail |
|---|---|
| Company | Actinium Pharmaceuticals, Inc. (ATNM) |
| Form Type | SC 13G |
| Filed Date | Jan 29, 2024 |
| Risk Level | low |
| Sentiment | bullish |
Complexity: simple
Sentiment: bullish
Topics: institutional-ownership, passive-investment, pharmaceuticals, SC-13G
TL;DR
**BlackRock just revealed a 5.1% stake in Actinium Pharma, a bullish signal for the stock.**
AI Summary
BlackRock Inc., a major investment firm, reported on January 29, 2024, that it holds a significant stake in Actinium Pharmaceuticals, Inc. As of December 31, 2023, BlackRock beneficially owned 2,478,579 shares of Actinium's Common Stock, representing 5.1% of the company. This filing indicates BlackRock's passive investment in the pharmaceutical company, signaling their confidence in Actinium's long-term prospects without seeking to influence management. For investors, this means a large, reputable institution sees value in Actinium, which can be a positive signal for the stock's stability and potential future growth.
Why It Matters
A major institutional investor like BlackRock holding a significant stake can lend credibility to Actinium Pharmaceuticals and potentially attract other investors, influencing stock price stability.
Risk Assessment
Risk Level: low — This filing indicates a passive investment by a large institution, generally seen as a positive or neutral event with low risk.
Analyst Insight
Smart investors might view BlackRock's 5.1% stake as a vote of confidence, prompting further research into Actinium Pharmaceuticals' fundamentals and future prospects, especially given the passive nature of the investment.
Key Numbers
- 2,478,579 — Shares Owned (The total number of Actinium Pharmaceuticals, Inc. common stock shares beneficially owned by BlackRock Inc.)
- 5.1% — Ownership Percentage (The percentage of Actinium Pharmaceuticals, Inc. common stock owned by BlackRock Inc., indicating a significant stake.)
- December 31, 2023 — Reporting Date (The specific date as of which BlackRock's ownership in Actinium Pharmaceuticals, Inc. is being reported.)
Key Players & Entities
- BlackRock Inc. (company) — the reporting person and institutional investor
- Actinium Pharmaceuticals, Inc. (company) — the subject company whose stock is being reported
- 2,478,579 (dollar_amount) — number of shares beneficially owned by BlackRock
- 5.1% (dollar_amount) — percentage of class of securities beneficially owned by BlackRock
- December 31, 2023 (person) — the date of the event requiring the filing
- January 29, 2024 (person) — the filing date of the SC 13G
Forward-Looking Statements
- BlackRock will maintain its passive investment in Actinium Pharmaceuticals for the foreseeable future. (BlackRock Inc.) — high confidence, target: December 31, 2024
- Actinium Pharmaceuticals' stock may experience increased investor confidence due to BlackRock's significant stake. (Actinium Pharmaceuticals, Inc.) — medium confidence, target: June 30, 2024
FAQ
Who filed this SC 13G statement regarding Actinium Pharmaceuticals, Inc.?
BlackRock Inc. filed this SC 13G statement, as indicated in the 'FILED BY' section of the filing.
What percentage of Actinium Pharmaceuticals, Inc.'s Common Stock does BlackRock Inc. beneficially own?
BlackRock Inc. beneficially owns 5.1% of Actinium Pharmaceuticals, Inc.'s Common Stock, as stated in the filing.
How many shares of Actinium Pharmaceuticals, Inc. Common Stock does BlackRock Inc. beneficially own?
BlackRock Inc. beneficially owns 2,478,579 shares of Actinium Pharmaceuticals, Inc. Common Stock.
What was the 'Date of Event Which Requires Filing of this Statement'?
The 'Date of Event Which Requires Filing of this Statement' was December 31, 2023.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13d-1(b), as indicated by the 'X' in the appropriate box.
Filing Details
This Form SC 13G (Form SC 13G) was filed with the SEC on January 29, 2024 by December 31, 2023 regarding Actinium Pharmaceuticals, Inc. (ATNM).